Sponsored by
This was a small, 12 patient study of an experimental treatment which had remarkable results. For DIPG, survival is usually about 8-12 months. With this treatment, average survival was 17 months, with acceptable side effects. This could be a big advance. Of course it is not good enough by itself, but opens up possibilities of combinations with other treatments to be a part of the ultimate cocktail cure. We need to fight for the promising pathway act to get access to these treatments now and to have the technology in place to figure out how best to use these treatments!